Sangamo Therapeutics (SGMO)

Executive Summary

Sangamo Therapeutics is a clinical-stage biotech company pioneering zinc finger protein-based genomic medicines. Its lead asset, ST-920 (isaralgagene civaparvovec), is a gene therapy for Fabry disease that has completed a Phase 1/2 trial with promising safety and efficacy data, supporting advancement to pivotal studies. The company also has active programs in kidney transplant rejection (TX200) and preclinical partnerships in hemophilia and sickle cell disease. Despite a lean pipeline, Sangamo's proprietary platform and strategic collaborations position it for potential value creation, though near-term execution and financing risks remain. The upcoming period is critical as the company seeks to initiate a Phase 3 trial for ST-920, secure additional partnerships, and advance its neurology pipeline.

Upcoming Catalysts (preview)

• H2 2026ST-920 Phase 3 trial initiation for Fabry disease70% success
• H2 2026TX200 Phase 1/2 data readout in kidney transplant rejection60% success
• H2 2026New partnership or licensing deal for CNS or other ZFP programs50% success